Absci Corporation (“Absci”) (NASDAQ: ABSI) is a generative AI drug creation company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins. Absci leverages its integrated drug creation platform to identify novel drug targets and create promising biotherapeutic candidates.
In order to optimize our website for you and to be able to continuously improve it, we use cookies. By continuing to use the website, you agree to the use of cookies. Further information on cookies can be found in our Privacy Policy.
